Minipuberty in females is ‘biphasic and prolonged’
Researchers report a “biphasic and prolonged” minipuberty in girls, and provide reference ranges for reproductive hormones during the first year of life.
Genotype may influence bisphosphonate response in osteogenesis imperfecta
Non-autosomal dominant inheritance and the presence of structural collagen defects are associated with reduced benefit of treatment with zoledronic acid in children with osteogenesis imperfecta, researchers report.
GHD reversal common, dependent on GH cutoff in diagnostic stimulation test
A systematic review and meta-analysis confirms a high rate of reversal of idiopathic growth hormone deficiency, albeit strongly dependent on the peak GH cutoff used.
Logistic issues hinder transition from paediatric to adult endocrine care
Dutch researchers have identified key logistic failures that may lead to adolescents with endocrine disorders failing to transition successfully from paediatric to adult tertiary care.
No influence of age on burosumab response in X-linked hypophosphatemia
Children with X-linked hypophosphatemia derive similar benefits from burosumab regardless of whether they start treatment before or after the age of 5 years, shows a post-hoc analysis of a randomised trial.
Weekly somatrogon noninferior to daily somatropin in paediatric GHD
Weekly injections of somatrogon result in similar height gains to daily somatropin treatment in children with growth hormone deficiency, show results of a 12-month phase 3 trial.
Increased peak GH response with oral GH secretagogue receptor agonist in children with GHD
An oral growth hormone secretagogue receptor agonist produces larger GH responses than standard stimulation tests in children with growth hormone deficiency, study findings suggest.
rhGH therapy boosts adult height among children with SHOX haploinsufficiency
A study of Brazilian children with isolated SHOX haploinsufficency who were followed up until adult height has demonstrated a long-term benefit of recombinant human growth hormone therapy with or without puberty modulator treatment.
Switch from daily to weekly rhGH feasible and popular for children with GHD
Children with growth hormone deficiency maintain their growth trajectories if they switch from a daily recombinant human growth hormone to weekly lonapegsomatropin, and the vast majority prefer the less frequent injections, show the results of the fliGHt trial.
Silver-Russell syndrome patients derive lasting height and BMI benefits from rhGH treatment
Treatment with recombinant human growth hormone results in an increased final adult height in children with molecularly confirmed Silver–Russell syndrome, as well as an improved BMI that persists after treatment cessation, say researchers.
